Suppr超能文献

相似文献

1
Oxalate homeostasis.
Nat Rev Nephrol. 2023 Feb;19(2):123-138. doi: 10.1038/s41581-022-00643-3. Epub 2022 Nov 3.
3
Sel1-like proteins and peptides are the major -derived factors stimulating oxalate transport by human intestinal epithelial cells.
Am J Physiol Cell Physiol. 2023 Jul 1;325(1):C344-C361. doi: 10.1152/ajpcell.00466.2021. Epub 2023 May 1.
4
Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
Nephrol Dial Transplant. 2019 Jun 1;34(6):908-914. doi: 10.1093/ndt/gfy239.
5
Future treatments for hyperoxaluria.
Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709.
9
NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.
Kidney Int. 2013 Nov;84(5):895-901. doi: 10.1038/ki.2013.207. Epub 2013 Jun 5.
10
Absence of the sulfate transporter SAT-1 has no impact on oxalate handling by mouse intestine and does not cause hyperoxaluria or hyperoxalemia.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G82-G94. doi: 10.1152/ajpgi.00299.2018. Epub 2018 Nov 1.

引用本文的文献

1
Comparison of Plasma Oxalate Measurement Methods in Patients With End-Stage Kidney Disease.
Kidney Int Rep. 2025 Mar 30;10(6):2045-2048. doi: 10.1016/j.ekir.2025.03.053. eCollection 2025 Jun.
3
Metabolic Insights into Urinary Stone Formation: Evidence from Mendelian Randomization, Clinical, and in vivo Studies.
Kidney Dis (Basel). 2025 Mar 29;11(1):240-257. doi: 10.1159/000545550. eCollection 2025 Jan-Dec.
4
Early Detection and Monitoring of Nephrolithiasis: The Potential of Electrochemical Sensors.
Sensors (Basel). 2025 Apr 17;25(8):2547. doi: 10.3390/s25082547.
6
Engineered Oxalate Decarboxylase Boosts Activity and Stability for Biological Applications.
ACS Omega. 2025 Mar 24;10(12):12375-12384. doi: 10.1021/acsomega.4c11434. eCollection 2025 Apr 1.
8
OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria.
Urolithiasis. 2025 Mar 5;53(1):47. doi: 10.1007/s00240-025-01698-0.
10
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.
Kidney Int Rep. 2024 Sep 1;9(11):3083-3096. doi: 10.1016/j.ekir.2024.08.031. eCollection 2024 Nov.

本文引用的文献

1
Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria.
NEJM Evid. 2022 Jul;1(7):EVIDoa2100053. doi: 10.1056/EVIDoa2100053. Epub 2022 May 6.
2
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
J Pharmacol Exp Ther. 2023 Jan;384(1):133-154. doi: 10.1124/jpet.122.001234. Epub 2022 Jun 9.
4
Calcium-Based Phosphate Binders and Plasma Oxalate Concentration in Dialysis Patients.
J Am Soc Nephrol. 2022 Jul;33(7):1427. doi: 10.1681/ASN.2022030248. Epub 2022 May 2.
5
CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146. doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9.
6
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC).
Kidney360. 2020 Sep 3;1(11):1284-1290. doi: 10.34067/KID.0001522020. eCollection 2020 Nov 25.
7
High Plasma Oxalate Levels Early After Kidney Transplantation Are Associated With Impaired Long-Term Outcomes.
Transpl Int. 2022 Mar 18;35:10240. doi: 10.3389/ti.2022.10240. eCollection 2022.
8
New therapeutics for primary hyperoxaluria type 1.
Curr Opin Nephrol Hypertens. 2022 Jul 1;31(4):344-350. doi: 10.1097/MNH.0000000000000790. Epub 2022 Mar 9.
10
Role of ROS-Induced NLRP3 Inflammasome Activation in the Formation of Calcium Oxalate Nephrolithiasis.
Front Immunol. 2022 Jan 27;13:818625. doi: 10.3389/fimmu.2022.818625. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验